Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC

(AGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Allergan says revenue from aesthetics unit may double by 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2018 | 01:49pm EST
The Allergan logo is seen in this photo illustration

NEW YORK (Reuters) - Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox.

Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

Chief Commercial Officer Bill Meury said Allergan expects revenue at its medical aesthetics unit to grow to $7 billion to $8 billion. That compares with revenue of $3.8 billion from the business in 2017.

Beyond Botox, the unit includes dermal filler Juvederm, the CoolSculpting fat-freezing systems, and other treatments.

He said the forecast implied an 8 to 10 percent compound annual growth rate.

Meury said the Bonti acquisition would allow the company to market a new "starter toxin." Patients could test drive the treatment, which lasts for two to four weeks, to help them decide if they want to use longer-term Botox.

Shares of Allergan fell 0.9 percent to $188.21 on Friday, while shares of Revance were down 1.1 percent and Evolus fell around 2.5 percent.

(The story corrects Allergan company stock price in final paragraph.)

(Reporting by Michael Erman; Editing by Chizu Nomiyama and Bernadette Baum)

By Michael Erman

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.29% 139.07 Delayed Quote.4.05%
EVOLUS INC 0.44% 27.38 Delayed Quote.130.08%
REVANCE THERAPEUTICS INC -0.79% 17.69 Delayed Quote.-12.12%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
09:12aALLERGAN : to Present at the 8th Annual SVB Leerink Global Healthcare Conference
AQ
02/15ALLERGAN 96 HOUR DEADLINE ALERT : Approximately 96 Hours Remain; Former Louisian..
BU
02/15ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/15ALLERGAN : to Present at The 8th Annual SVB Leerink Global Healthcare Conference
PR
02/14ALLERGAN PLC : Ex-dividend day for
FA
02/08ALLERGAN PLC : Other Events (form 8-K)
AQ
02/06EVOLUS : rockets after FDA approves wrinkle treatment to rival Allergan`s Botox
AQ
02/05ALLERGAN : Appaloosa steps up pressure on Allergan to split chairman, CEO roles
RE
02/04Papa John's, Evolus rise; Gannett, Allergan slip
AQ
02/01ALLERGAN ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of L..
BU
More news
Financials ($)
Sales 2019 15 162 M
EBIT 2019 7 090 M
Net income 2019 145 M
Debt 2019 18 297 M
Yield 2019 2,12%
P/E ratio 2019 590,28
P/E ratio 2020 66,42
EV / Sales 2019 4,26x
EV / Sales 2020 3,87x
Capitalization 46 257 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 190 $
Spread / Average Target 37%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC4.05%46 906
JOHNSON & JOHNSON5.68%365 768
PFIZER-2.86%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536